We have two different questions going on that will take smarter people than I to answer, but they are mathematical problems. Using your logic I showed that holding back the vaccine to give both shots resulted in more deaths then a single dose at a lower efficacy.
But… moving beyond that.
The problems, as I see it, is thinking of this in terms of a snapshot in time when in actuality we need to examine it in terms of change over time.
There are a couple of different factors that need to be thought through, and it should have already been thought through by this time. One is the medical aspect, 96% v. 82% efficacy. The other is a logistical problem which is a function of manufacturing and distribution.
Manufacturing is being ramped up and millions, hundreds of millions of doses are on the way from both Phizer and Moderna, not counting another vaccine getting a EUA. The manufacturing side of the equation has to determine how many doses can be manufactured over X days, weeks. The logistics side is getting those doses to the place they are needed.
My undergrad degree is in Industrial Technology and part of that was an examination of transition from the traditional manufacturing model (parts on-hand and in local storage) to “Just In Time” manufacturing where the supply line always has product on the way and what is delivered today, is used in manufacturing tomorrow and finished product shipped out. The sample supply chain management principals can be applied to the manufacture of vaccine and its distribution to put doses in the locations they are need to be put in arms.
What that means from a science, manufacturing, distribution perspective is there may not be the need to obtain two doses per person, give one shot and let the other dose sit in a freezer for 3 (Pfizer) or 4 weeks (Moderna) just waiting for the second dose. With a balanced and tuned supply chain a large percentage of those 2nd doses held in reserve can actually be delivered as shots in arms now. That with the understanding that the supply chain will be able to deliver the 2nd dose to be at the correct distributions centers shortly before they are needed for the 2nd dose.
.
.
.
.
.
.
So in actuality, I’m squarely in the 2 dose regiment as the vaccine was tested to produce maximum efficacy. However science, manufacturing, and supply chain management says that not all those 2nd doses need to sit around for weeks.
Follow the manufacturers approved dosage regime, but tune the logistics.
.
.
.
.WW, PSHS